Telomerase-IN-9 

Telomerase-IN-9 is a potent and selective telomerase inhibitor. Telomerase-IN-9 significantly reduces telomerase activity by binding to hTERT, leading to decreased telomerase function. Telomerase-IN-9 induces apoptosis and inhibits colony formation. Telomerase-IN-9 reduces tumor burden, restores antioxidantbalance, and preserves lung architecture in a Benzo[a]pyrene (HY-107377)-induced lung cancer mouse model. Telomerase-IN-9 can be used for the research of lung cancer^[1].

Telomerase-IN-9 (compound 28) (48 h) exhibits potent and selective cytotoxicity against A549, MDA-MB-231, NCI-H460 cells, with IC₅₀s of 0.043, 0.926, and 1.08 μM, resectively, and shows low cytotoxicity on Vero cells with IC₅₀ < 25 μM^[1].
Telomerase-IN-9 (5-10 μM, 48 h) induces apoptosis in A549 cells in a dose-dependent manner^[1].
Telomerase-IN-9 (10 μM) significantly inhibits telomerase activity in A549 cells, with a fold change of 0.535^[1].
Telomerase-IN-9 (3.75-25 μM, 12 days) reduces colony formation in A549 cells in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

388.49

C₂₂H₂₀N₄OS

COC1=CC2C(NC3=NN=C(C4=CC=CC=C4)S3)C5=CC=CC=C5NC2C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Vishwakarma K, et al. Targeting telomerase for lung cancer: design and synthesis of acridine hybrids with in vitro and in vivo evaluation. Bioorg Med Chem Lett. 2026;131:130465.  [Content Brief]